Establishment Labs downgraded by Citigroup with a new price target
$ESTA
Industrial Specialties
Health Care
Citigroup downgraded Establishment Labs from Buy to Neutral and set a new price target of $60.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2025 | $60.00 | Buy | Canaccord Genuity |
| 5/16/2025 | $62.00 | Buy | BTIG Research |
| 5/14/2025 | $48.00 | Hold → Buy | Needham |
| 4/14/2025 | Hold | Needham | |
| 5/22/2024 | $60.00 | Buy → Neutral | Citigroup |
| 8/31/2023 | $75.00 | Overweight | JP Morgan |
| 6/29/2023 | $79.00 | Buy | Citigroup |
| 10/14/2022 | $90.00 | Overweight | Stephens |
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
Revenue for the quarter ended December 31, 2025 is expected to be between $64.0 million and $65.0 million, including between $17.0 million and $17.5 million from Motiva sales in the United States. Revenue for fiscal year 2025 is expected to be in the range of $210.5 million to $211.5 million, representing growth of approximately 27% over 2024, including between $45.4 million and $45.9 million from Motiva sales in the United States. The Company's year-end 2025 cash position is expected to be approximately $75.5 million, an increase of $4.8 million from the end of the third quarter of 2025. Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 44th Annual J.P Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT. A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the events. About Establishment Labs Establishmen
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted Motiva® implants for approval in primary and revision breast reconstruction to the U.S. Food and Drug Administration (FDA). The products were previously approved by the FDA for use in breast augmentation on September 27, 2024. "Expanding our FDA approval from breast augmentation to reconstruction is an important step forward for women's health," said Jeff Ehrhardt, Senior Vice President and Establishment Labs' General Manager of North America. "Breast reconstruction
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
Canaccord Genuity initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $60.00
BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00
Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
SCHEDULE 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision
Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2025. Third Quarter Highlights and Outlook (Unaudited) Third quarter worldwide revenue of $53.8 million, an increase of 33.8% from the year ago period. Revenue included $11.9 million of Motiva sales in the United States. 2025 revenue expected to exceed $210 million, an increase from previous guidance of $208 million to $212 million. Third quarter gross margin of 70.1% compared to 63.9% in the year-ago period and 68.8% in th
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750830. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the United States. 2025 revenue guidance increased to $208 million to $212 million from $205 million to $210 million, year over year growth of 25%–28%, with at least $40 million in US Motiva revenue. Second quarter gross ma